Immunogenicity 426

summary
Sample ID
None
Response
Negative
Tumor Type
Melanoma
Gene Symbol
FIGN
Transcript ID
None
HLA INFO
B*35:01
TCR INFO

No TCR info found!

T cell Tumor cell B*35:01
sequence
Full length protein sequence (759 aa)
MISST
1
SVYGL
6
KMQWT
11
PEHAQ
16
WPEQH
21
FDITS
26
TTRSP
31
AHKVE
36
AYRGH
41
LQRTY
46
QYAWA
51
NDDIS
56
ALTAS
61
NLLKK
66
YAEKY
71
SGILE
76
GPVDR
81
PVLSN
86
YSDTP
91
SGLVN
96
GRKNE
101
SEPWQ
106
PSLNS
111
EAVYP
116
MNCVP
121
DVITA
126
SKAGV
131
SSALP
136
PADVS
141
ASIGS
146
SPGVA
151
SNLTE
156
PSYSS
161
STCGS
166
HTVPS
171
LHAGL
176
PSQEY
181
APGYN
186
GSYLH
191
STYSS
196
QPAPA
201
LPSPH
206
PSPLH
211
SSGLL
216
QPPPP
221
PPPPP
226
ALVPG
231
YNGTS
236
NLSSY
241
SYPSA
246
SYPPQ
251
TAVGS
256
GYSPG
261
GAPPP
266
PSAYL
271
PSGIP
276
APTPL
281
PPTTV
286
PGYTY
291
QGHGL
296
TPIAP
301
SALTN
306
SSASS
311
LKRKA
316
FYMAG
321
QGDMD
326
SSYGN
331
YSYGQ
336
QRSTQ
341
SPMYR
346
MPDNS
351
ISNTN
356
RGNGF
361
DRSAE
366
TSSLA
371
FKPTK
376
QLMSS
381
EQQRK
386
FSSQS
391
SRALT
396
PPSYS
401
TAKNS
406
LGSRS
411
SESFG
416
KYTSP
421
VMSEH
426
GDEHR
431
QLLSH
436
PMQGP
441
GLRAA
446
TSSNH
451
SVDEQ
456
LKNTD
461
THLID
466
LVTNE
471
IITQG
476
PPVDW
481
NDIAG
486
LDLVK
491
AVIKE
496
EVLWP
501
VLRSD
506
AFSGL
511
TALPR
516
SILLF
521
GPRGT
526
GKTLL
531
GRCIA
536
SQLGA
541
TFFKI
546
AGSGL
551
VAKWL
556
GEAEK
561
IIHAS
566
FLVAR
571
CRQPS
576
VIFVS
581
DIDML
586
LSSQV
591
NEEHS
596
PVSRM
601
RTEFL
606
MQLDT
611
VLTSA
616
EDQIV
621
VICAT
626
SKPEE
631
IDESL
636
RRYFM
641
KRLLI
646
PLPDS
651
TARHQ
656
IIVQL
661
LSQHN
666
YCLND
671
KEFAL
676
LVQRT
681
EGFSG
686
LDVAH
691
LCQEA
696
VVGPL
701
HAMPA
706
TDLSA
711
IMPSQ
716
LRPVT
721
YQDFE
726
NAFCK
731
IQPSI
736
SQKEL
741
DMYVE
746
WNKMF
751
GCSQ
756
Mutation Information
DNA mutation:
None
Peptide Range:
516 ~ 534
Mut AA position:
520 (5 in Wild Type peptide)
Alignment
Wild Type:
"-------TALPRSILLF--
||||.|||||
Mutant:
SDAFSGLTALPQSILLFGP"
reference

Nature, 2017

An immunogenic personal neoantigen vaccine for patients with melanoma

Gene Name (from Reference) FIGN

clinic trial
Checkpoint Blockade

None

ACT

None

Vaccination

None

Curative Effect

None

experiment
minimal_peptide

None

Antigen Type

None

T-cell Source

PBMCs

APC Type

autologous APCs

Assay

IFNg ELISPOT assay